このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Intermittent Hypoxemia and Acute Kidney Injury Study (IHAKI Study) (IHAKI)

2019年8月29日 更新者:Elie G. Abu Jawdeh, MD

This pilot study aims at investigating the relationship between intermittent hypoxemia (IH) and acute kidney injury (AKI) in preterm infants.

AIM 1: Test the hypothesis that intermittent hypoxemia is associated kidney injury in preterm infants, as reflected by a rise in serum creatinine.

AIM 2: Test the hypothesis that there is rise in acute kidney injury urinary biomarkers with increased intermittent hypoxemia.

調査の概要

詳細な説明

BACKGROUND:

Preterm birth is a major health care concern and although survival of premature infants has improved, the incidence of neonatal morbidities has slightly decreased especially in cases of extreme prematurity. Apnea of prematurity (immature respiratory control) is a major complication in Neonatal Intensive Care Units occurring in virtually all infants born before 28 weeks gestation. Intermittent Hypoxemia (IH), episodic oxygen desaturation events, is generally attributed to apnea of prematurity often superimposed upon suboptimal lung function. Intermittent hypoxemia events are common in preterm infants and may lead to both short-term and long-term morbidities. Typically, the incidence of intermittent hypoxemia (IH) increases over the first 4 weeks of life before plateauing at weeks 6-8. In addition to inducing oxidative stress by increasing production of reactive oxygen species, this hypoxemia/reoxygenation cycle is thought to induce a pro-inflammatory cascade of transcription factors that promotes activation of inflammatory cells resulting in multisystem morbidity. These morbidities include retinopathy of prematurity, cardiorespiratory instability, and poor neurodevelopmental outcomes. A potential morbidity that has yet to be investigated is acute kidney injury (AKI).

AKI is associated with morbidity and mortality in critically ill neonates. The risk of AKI is higher in very low birth weight infants requiring assisted ventilation and ionotropic support, and in infants with congenital heart disease. Additionally, AKI occurs more frequently in infants who suffered severe birth asphyxia. While it has been established that end-stage kidney disease (ESKD) is associated with worsening sleep apnea in adults, it has been proposed that sleep apnea and nocturnal hypoxemia may contribute to kidney injury, the development of chronic kidney disease (CKD), and the progression to kidney failure. Proposed mechanisms of kidney disease via intermittent nocturnal hypoxemia include 1: direct intrarenal hypoxemia (resulting in tubulointerstitial injury) 2: an increase in oxidative stress, inflammatory cytokines, and systemic blood pressure (via activation of the renin-angiotensin system). Hence It is plausible that IH may modulate AKI in preterm neonates. The investigators goal is to test the hypothesis that intermittent hypoxemia is associated with Acute Kidney Injury in preterm infants. Investigation of relationship between IH and AKI may provide further insight into onset and prevention given the recent advancements in the detection and characterization of AKI in this vulnerable population.

SPECIFIC AIMS:

AIM 1: Test the hypothesis that intermittent hypoxemia is associated kidney injury in preterm infants, as reflected by a rise in serum creatinine.

APPROACH: Premature infants with GA 23 to 31 weeks will be prospectively recruited from Kentucky Children's Hospital Neonatal Intensive Care Unit (NICU). High resolution oxygen saturation monitoring will be performed for the first 2 months of life. Creatinine levels will be collected as they are obtained routinely on premature infants in the NICU. Demographic data will be collected including gestational age, postnatal age, gender and race. Clinical data including respiratory support, caffeine use, vital signs and neonatal morbidities will be documented. Scores to predict severity of disease and mortality in newborns will be used. The investigators will assess the cumulative effect of IH on AKI as reflected by serum creatinine measurements at 1 month, 2 months, and discharge in extremely preterm infants.

AIM 2: Test the hypothesis that there is rise in acute kidney injury urinary biomarkers with increased intermittent hypoxemia.

APPROACH: Similar to Aim 1, premature infants with GA 23 to 31 weeks will be prospectively recruited from Kentucky Children's Hospital Neonatal Intensive Care Unit (NICU). High resolution oxygen saturation monitoring will be performed for the first 2 months of life. Urine will be collected daily in the first week of life and then weekly until 2 months of age and hospital discharge. Collecting urine is noninvasive and minimal risk. Samples will be de-identified and stored in the investigators research laboratory. Standardized kits to measure biomarkers associated with kidney injury such as albumin, β2-microglobulin (β2MG), cystatin C (Cys C), epidermal growth factor (EGF), neutrophil gelatinase associated lipocalin (NGAL), osteopontin (OPN), and uromodulin (UMOD) will be used. Since IH increases with age and persists during NICU stay, the cumulative effect of intermittent hypoxemia will be correlated with biomarker concentrations weekly throughout the study period and at discharge.

Oxygen saturation will be continuously monitored upon admission with high resolution pulse oximeters, with 2 second averaging time and 1Hz sampling rate. Novel software will be utilized to analyze raw data per the following definitions:

  1. Intermittent Hypoxemia is primarily defined as a drop in oxygen saturation (SpO2) to less than 80% for more than 4 seconds and less than 3 minutes.

    Secondary measures for IH include:

  2. A drop in SpO2 of <85% for >4 seconds and <3 minutes duration
  3. A decline in SpO2 by >4% from baseline to <90% that lasted >4 seconds
  4. Percent time spent below above threshold, includes sustained hypoxemia (>3min duration)
  5. Number of hyperoxemic events defined as an increase in SpO2 of >95%
  6. Duration and nadir of each oxygen desaturation and hyperoxemic event
  7. Mean SpO2/day

Sample size: There is no data available in the literature to calculate sample size. Based on NICU census, consent success rate, and accounting for data loss, the investigators will recruit a total of 50 patients for this pilot project. To maintain a balanced sample, the investigators will stratify enrollment by gestational age targeting 15-18 subjects in each of the following groups: 23-25 weeks gestation, 26-28 weeks gestation, 29-31 weeks gestation.

研究の種類

観察的

入学 (実際)

41

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Kentucky
      • Lexington、Kentucky、アメリカ、40536
        • University of Kentucky - Kentucky Children's Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

2ヶ月歳未満 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

Preterm infants less than 32 weeks gestational age.

説明

Inclusion Criteria:

  • Preterm infants less than 32 weeks gestational age admitted to University of Kentucky neonatal intensive care unit

Exclusion Criteria:

  • Major congenital malformations

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
Test the hypothesis that intermittent hypoxemia is associated with acute kidney injury, as reflected by a rise in creatinine or urinary biomarkers
時間枠:1 year
1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Elie G Abu Jawdeh, MD、University of Kentucky
  • 主任研究者:Mina H Hanna, MD、University of Kentucky

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2016年7月1日

一次修了 (実際)

2018年1月15日

研究の完了 (実際)

2018年1月15日

試験登録日

最初に提出

2016年7月14日

QC基準を満たした最初の提出物

2016年7月18日

最初の投稿 (見積もり)

2016年7月19日

学習記録の更新

投稿された最後の更新 (実際)

2019年9月4日

QC基準を満たした最後の更新が送信されました

2019年8月29日

最終確認日

2019年8月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する